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AbstrAct
Lipogenesis inhibition was reported to induce apoptosis and repress proliferation 
of cancer cells while barely affecting normal cells. Lipins exhibit dual function as 
enzymes catalyzing the dephosphorylation of phosphatidic acid to diacylglycerol and 
as co-transcriptional regulators. Thus, they are able to regulate lipid homeostasis at 
several nodal points. Here, we show that lipin-1 is up-regulated in several cancer cell 
lines and overexpressed in 50 % of high grade prostate cancers. The proliferation 
of prostate and breast cancer cells, but not of non-tumorigenic cells, was repressed 
upon lipin-1 knock-down. Lipin-1 depletion also decreased cancer cell migration 
through RhoA activation. Lipin-1 silencing did not significantly affect global lipid 
synthesis but enhanced the cellular concentration of phosphatidic acid. In parallel, 
autophagy was induced while AKT and ribosomal protein S6 phosphorylation were 
repressed. We also observed a compensatory regulation between lipin-1 and lipin-2 
and demonstrated that their co-silencing aggravates the phenotype induced by 
lipin-1 silencing alone. Most interestingly, lipin-1 depletion or lipins inhibition with 
propranolol sensitized cancer cells to rapamycin. These data indicate that lipin-1 
controls main cellular processes involved in cancer progression and that its targeting, 
alone or in combination with other treatments, could open new avenues in anticancer 
therapy.
IntroductIon
Alterations of various metabolic pathways are 
frequently noticed in cancer cells. Among them, the most 
documented is increased glucose consumption through 
aerobic glycolysis known as the “Warburg effect”. 
However, other metabolic processes, such as protein, 
nucleic acid and lipid biosynthesis, are also deregulated in 
cancer cells [1]. This metabolic reprogramming is needed 
to meet the increased requirements of highly proliferating 
cancer cells for energy and building blocks. In the case of 
lipids, their increased biosynthetic rate provides material 
required for cell membranes formation and energy storage. 
In addition, lipids play also significant roles as signaling 
molecules. The alteration of their abundance can affect 
crucial processes necessary for cell transformation such 
as migration, invasion and tumor angiogenesis [2]. 
Finally, lipids are also required for protein modifications 
that critically regulate their functions and are involved 
in protein and organelle turnover through autophagy 
regulation [2]. Thus, the various roles of lipids make 
them essential components of the cellular machinery 
regulating the phenotype of cancer cells. Since the pivotal 
observation that Fatty Acid Synthase (FASN) is a potential 
target for anticancer therapy [3], much effort has been 
devoted to targeting key enzymes of lipid biosynthesis. 
Inhibition of fatty acid synthesis by pharmacological tools 
or targeting key enzymes with siRNA results in inhibition 
of cancer cell proliferation or cell death [4-7]. 
Although lipid homeostasis deregulation is observed 
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in many different cancer types, it is especially critical in 
prostate cancer where the classical “glycolysis-switch” 
is not observed [8]. Targeting key enzymes of lipid 
biosynthesis appears therefore as a promising approach 
to fight prostate cancer [9]. However, numerous enzymes 
are involved in lipid biosynthesis and the specific role of 
many of them during cancer progression is still unknown 
[10]. This is the case for lipin-1, one of the three members 
of the lipins family. Lipin-1 is involved in the regulation of 
triglyceride and phospholipid biosynthesis by catalyzing 
the dephosphorylation of phosphatidate into diacylglycerol 
(DAG) [11]. It acts also as a co-regulator of transcription 
and, as such, can up-regulate fatty acids uptake and 
oxidation, TCA cycle and mitochondrial metabolism 
genes. Thus, due to its dual function as enzyme and co-
transcriptional regulator, lipin-1 is able to regulate lipid 
homeostasis at several nodal points [12]. Very recently, 
it was also described as being involved in the late phase 
of autophagy [13], a key cellular function contributing to 
cancer progression in a context-dependent manner [14]. 
Here, we show that lipin-1expression is increased 
in various cancer cell types both in vitro and in vivo in 
human prostate tumor samples. The specific inhibition of 
lipin-1 in prostate and breast cancer cells demonstrates 
its critical importance for cell proliferation and migration 
through deregulation of several intracellular signaling 
pathways. This study demonstrates for the first time that 
the targeting of lipin-1 is a potential new anti-cancer 
strategy that could be used alone or in combination with 
drugs like rapamycin.
results
expression of lipin-1 in cancer 
We previously identified lipin-1 by microarray as 
a Rac1-regulated gene in the prostate adenocarcinoma 
cell line PC-3 (personal observation). This regulation 
was validated here at the protein level by silencing Rac1 
with two different siRNA that resulted in lipin-1 down-
regulation (Fig.1A). RT-qPCR measurements indicate that 
Rac1 silencing significantly decreased (δδCt of -0.9) the 
Fig.1: lipin-1 expression is increased in various cancer cell lines and in prostate cancer samples. (A) Lipin-1 is positively 
regulated by Rac1. 48 h after transfection with two different siRNA targeting Rac1 (siRac1(1) and siRac1(2)), with a control siRNA (Scr) 
or without sirna (mock) PC-3 cells were lysed and analysed by immuno-blotting with specific antibodies to lipin-1, Rac1 and Erk1/2. (B) 
Lipin-1 is highly expressed in various cancer cell lines as compared to fibroblasts and endothelial cells. Fibroblasts (FIBRO), endothelial 
cells (LT2), A2058, Hs578T, MCF7 and HT1080 cells were lysed and analysed by immuno-blotting with specific antibodies to lipin-1 and 
Erk1,2. (C) Lipin-1 is highly expressed in the most aggressive prostatic cancer cell lines. PNT1A, LnCaP, C4-2B and PC-3 cells were lysed 
and analyzed by immuno-blotting with specific antibodies to lipin-1 and Erk1,2. (D) Representative images of sections of normal human 
prostate (up) and of high grade prostate adenocarcinoma positive for anti-lipin-1 labelling (down) are shown. The 19 normal prostate tissues 
tested were negative while 16 out of 30 high-grade prostate adenocarcinomas were labelled with anti-lipin-1 antibodies. Bars = 50 µm.
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lipin-1 gene expression confirming that this regulation 
occurred, at least partly, at the transcriptional level. As 
Rac1 is frequently over-expressed or over-activated in 
cancers [15-18], we reasoned that lipin-1 might also be 
over-expressed in various cancer cell lines as compared 
to normal skin fibroblasts or endothelial cells (Fig.1B and 
1C). Its expression was stronger in the highly tumorigenic 
PC-3 and C4-2B prostatic cell lines than in the low- or 
non-tumorigenic prostatic cells (LnCaP and PNT1A, 
respectively). Lipin-1 was also found highly expressed 
in prostatic cancers in vivo since 16 out of 30 high-grade 
human prostate adenocarcinomas were stained with anti-
lipin-1 antibodies. By contrast, the 19 tested normal 
prostate tissues were all negative. As illustrated in Fig.1D, 
the staining was observed only in epithelial cells and never 
in stromal cells and was almost exclusively cytoplasmic.
lipin-1 silencing repressed cell proliferation in 
cancer cells
Lipin-1 was silenced by RNAi to evaluate its 
importance for cell phenotype. As observed by Western 
blot analysis, lipin-1 expression was strongly repressed 
after transfection with specific siRNA in all cell types 
tested in the proliferation assay (Fig.2). This inhibition 
lasted for at least 4 days and started to recover at day 5 
Fig.2: lipin-1 silencing repressed proliferation of prostate adenocarcinoma and breast adenocarcinoma cells (Pc-
3 and Hs578T) but not proliferation of normal prostate epithelial cells (PNT1A) and human fibroblasts (FIBRO). 
Immediately after transfection with a control siRNA (Scr) or with a siRNA targeting lipin-1 (siLipin1(1) or siLipin1(2)) cells were seeded in 
24-well plates and collected at the indicated times. The DNA content of each well was measured as described in “Materials and Methods”. 
***: p< 0.001 as determined by ANOVA followed by Tukey-Kramer analysis.
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post-transfection (Supplemental Fig. 1). Lipin-1 inhibition 
did not affect PC-3 cell survival, as assessed by apoptosis 
measurements (Supplemental Fig. 2), but repressed their 
proliferation rate as assessed by DNA measurements 
and cell counting (Fig.2A and Supplemental Fig.3). 
This effect was not limited to PC-3 cells as silencing of 
lipin-1 in breast adenocarcinoma cells (Hs578T) also 
reduced significantly their proliferation rate (Fig. 2B). 
Despite an efficient silencing of lipin-1, control cells 
(normal human skin fibroblasts and the non-tumorigenic 
prostatic cell line PNT1A) were not affected by lipin-1 
repression suggesting that non-tumorigenic cells are less 
sensitive to lipin-1 depletion (Fig.2C and Fig.2D). The 
second lipin-1 siRNA that is more efficient in silencing 
lipin-1 tends also to be more efficient in reducing cancer 
cell proliferation (compare Fig.2A to Fig.2E and Fig.2B 
to Fig.2F). A similar repression of proliferation of PC-3 
cells was also observed in lipid-free medium suggesting 
that extracellular lipids are not involved in this process 
(Supplemental Fig.4). 
lipin-1 silencing represses Pc-3 cells migration 
through rhoA activation
To further evaluate the relevance of the silencing of 
lipin-1 on cellular functions involved in tumorigenesis, 
we evaluated its effect on the migratory properties of 
PC-3 cells. In a scratch wound healing assay, lipin-1 
silencing decreased the migration of PC-3 cells (Fig.3). 
As RhoGTPases are key regulators of cellular migration 
[19], the level of the active form of RhoA and Rac1 was 
measured by mean of a pull-down assay. We observed 
that the activity of RhoA was increased following lipin-1 
silencing (Fig.4A) while the activity of Rac1 was not 
significantly altered (Fig.4B). As we previously reported 
that an excess of RhoA activity can repress migration of 
PC-3 cells [20], a simultaneous repression of lipin-1 and 
RhoA was performed. As illustrated in Figure 4C, both 
proteins were efficiently silenced and the repression of cell 
migration due to lipin-1 silencing was abolished (Fig.4D). 
RhoA silencing alone did not affect the migration rate, 
indicating that the reversal of the inhibitory effect of 
lipin-1 silencing is not due to a nonspecific increase of 
Fig.3: lipin-1 silencing repressed cell migration. Immediately after transfection with the indicated siRNA, cells were processed 
for the migration assay as described in “Materials and Methods”. Representative phase contrast micrographs were taken immediately after 
releasing the insert (0 h) and 16 hours later (16 h). Bar = 250 µm. ***: p<0.001 as determined by ANOVA followed by Tukey-Kramer 
analysis. 
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the migration rate (Fig.4D). By contrast, the depletion of 
RhoA did not reverse the effect of lipin-1 silencing on 
proliferation (Supplemental Fig.5).
lipin-1 silencing regulates genes and pathways 
involved in cell metabolism
Lipin-1 has emerged as a crucial lipid regulator 
acting either as an enzyme or a co-regulator of 
transcription [12]. The silencing of lipin-1 did neither 
significantly affect the whole lipid synthesis nor 
Fig.4: lipin-1 silencing increased rhoA activity while rac1 activity was not altered. 48 h after transfection with the indicated 
siRNA, cells were processed for the GTPase activity assay as described in “Materials and Methods” and Western blot analysis with specific 
antibodies to RhoA, Rac1, and Erk1/2. Representative analyses for RhoA (A) and Rac1 (B) activity are illustrated. The results of each graph 
are expressed as mean ± s.d. of three independent experiments. (C-D) The repression of migration following Lipin-1 silencing is rescued by 
co-silencing of RhoA. Immediately after transfection with a control siRNA (Scr), a siRNA targeting lipin-1 (siLipin1), a control siRNA and 
a siRNA targeting RhoA (scr+siA1) or with a siRNA targeting lipin-1 and a siRNA targeting RhoA (siLipin1+siRhoA), cells were processed 
for the wound healing assay as described in “Materials and Methods”. An aliquot of the cell suspension was seeded in a dish and collected 
48 h after transfection for western blot analysis with specific antibodies to lipin-1, RhoA and Erk1/2 to control the efficiency of silencing 
(C). (D) Representative phase contrast micrographs were taken immediately after releasing the insert (0 h) and 16 hours later (16 h). Bar 
= 250 µm. N.S.: not significant, *: p<0.01 and ***: p<0.001 as determined by ANOVA followed by Tukey-Kramer analysis. The graphs 
summarize the results of three independent experiments expressed as means ± s.d. 
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triglyceride concentration nor the expression of fatty 
acid synthase but increased the cellular concentration of 
phosphatidic acid (PA) (Supplemental Fig.6). By contrast, 
it repressed the mRNA expression of ATP citrate lyase 
(Supplemental Fig.6), a cytosolic enzyme that catalyzes 
the generation of acetyl-CoA from citrate and is over-
expressed in several types of cancers [6]. A decreased 
phosphorylation of AKT and of ribosomal protein S6 was 
also observed upon lipin-1 silencing (Fig.5A and Fig.5B). 
Autophagy is often induced in cancer cells in order to 
maintain a high metabolic rate [14]. We observed that the 
repression of lipin-1 induced an accumulation of LC3-II 
while p62/SQSTM1 level was not altered (Fig.5C) and 
the amount of LC3-II further increased in the presence 
of the lysosomal inhibitor E64d (Fig.5D). Moreover, 
cells expressing a double tagged LC3 (RFP-GFP-LC3) 
and silenced or not for lipin-1 displayed comparable 
percentages of autophagosomes (Fig.5E and Fig.5F), 
suggesting that the accumulation of LC3-II is not due 
to a blockage of autophagosome maturation. These data 
support an enhanced autophagic flux following lipin-1 
silencing that could help cells to counteract the negative 
effect of lipin-1 down-regulation.
Fig.5: lipin-1 silencing inhibited AKt and ribosomal protein s6 phosphorylation and enhanced autophagy. PC-3 cells 
were transfected with the indicated siRNA. (A-D) 48 hours after transfection, cells were processed for Western blotting and analyzed with 
specific antibodies to AKT, Phospho-AKT (ser473), ribosomal protein S6, phospho ribosomal protein S6 (ser235/236), LC3 and Erk1/2. 
The results of each graph are expressed as mean ± s.d. of three independent experiments. In D, cells were treated or not with 10 µg/ml 
of the lysosomal protease inhibitor E64d (+E64d). In E and F, cells were first transfected with an expression vector for RFP-GFP-LC3B 
as described in “Materials and Methods” and after transfected with the indicated siRNA. In E, the graph represents the percentages of 
autophagosomes calculated in more than 50 cells per condition as described in “Materials and Methods” expressed as mean ± s.d. In F, 
representative fluorescent micrographs are shown. Bar = 10 µm *: p<0.05 and ***: p< 0.001 as determined by ANOVA followed by Tukey-
Kramer analysis.
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Manipulation of lipin-1 amount induced a 
compensatory regulation of lipin-2
A reciprocal regulation between lipin-1 and -2, but 
not lipin-3, was recently reported [21]. As lipin-1 and 
lipin-2 share common functions, an increased lipin-2 
expression could partly rescue lipin-1 silencing. As 
illustrated in Figure 6A, silencing of lipin-1 induced 
an increased expression of lipin-2 in PC-3 cells. This 
regulation was also observed in Hs578T cells but not in 
human fibroblasts or in control prostatic PNT1A cells 
(Supplemental Fig.7). On the reverse, over-expression of 
lipin-1 by clones expressing lipin-1 (PC-3/TR/Lipin1) in 
a doxycycline-dependent way induced a compensatory 
down-regulation of lipin-2. This effect depends on the 
catalytic activity of lipin-1 since over-expression of the 
phosphatase-dead mutant lipin-1D678E does not influence 
the level of lipin-2. The low level of lipin-3 expression 
relative to that of lipin-1 and lipin-2 (~10 fold lower) 
as evaluated by RT-qPCR and the lack of compensatory 
mechanism with the two other lipins [21] motivated us to 
not further investigate lipin-3 here.
Fig.6: compensatory regulation between lipin-1 and -2 affects Pc-3 phenotype. (A) There is a compensatory regulation of 
lipin-2 protein level following modulation of lipin-1 protein level that is dependent on lipin-1 activity. 48 hours after transfection of the 
indicated siRNA in PC-3 cells or after induction (+dox) of the expression of lipin-1 (in PC-3/TR/lipin1) or of the expression of inactive 
lipin-1 (in PC-3/TR/lipin-1DE), cells were lysed and analyzsed results of three independent experiments. (B) The inhibition of proliferation 
mediated by lipin-1 silencing was enhanced following co-silencing of lipin-2. Immediately after transfection with 20 (Scr) or 40 (Scr[2X]) 
nM of a control siRNA, 20 nM of the first siRNA targeting lipin-1 (siLipin1) or 20 nM of the first siRNA targeting lipin-1+ 20 nM of an 
siRNA targeting lipin-2 (siLipin1+siLipin2) cells were seeded in 24-well plates and collected at the indicated times. The DNA content of 
each well was measured as described in “Materials and Methods”. The insert shows Western blot analysis of cell lysates collected 48 h after 
transfection with the indicated siRNA with specific antibodies to lipin-1, lipin-2 and Erk1/2. *: p<0.05, **: p<0.01 and ***: p< 0.001 as 
determined by ANOVA followed by Tukey-Kramer analysis.
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lipin-1 and lipin-2 cooperate to regulate cell 
proliferation but not cell migration
In order to investigate the consequences of the 
compensatory increased level of lipin-2 following lipin-1 
silencing, we targeted also lipin-2 through RNAi (insert, 
Fig.6B). The double silencing of lipin-1 and lipin-2 
was very efficient and inhibited cell proliferation more 
strongly than the lipin-1 silencing alone, which shows 
that lipin-2 can partially compensate for the lack of lipin-1 
in this model. By contrast, the inhibition of migration of 
PC-3 cells was not affected by the depletion of lipin-2 
(Supplemental Fig.8). Altogether, these data demonstrate 
that lipin-1 and lipin-2 are both involved in the control of 
tumoral cells proliferation but that only lipin-1 regulates 
cell migration.
Pharmacological inhibition confirmed the role of 
lipins in the regulation of cell phenotype 
As a chemical alternative to RNAi, lipins 
activity can also be inhibited by propranolol [22-
24]. Pharmacological concentrations of propranolol 
significantly inhibited PC-3 cell proliferation and 
Fig.7: Propranolol inhibited Pc-3 cell proliferation and migration. PC-3 cells were treated with 100 µM propranolol (propr). 
(A) The DNA content of each well was measured as described in “Materials and Methods”. (B) Cells were processed for the migration 
assay as described in “Materials and Methods”. Propranolol was added just after the removal of the inserts. Representative phase contrast 
micrographs were taken immediately after releasing the insert (0 h) and 16 hours later (16 h). Bar = 250 µm. ***: p<0.001 as determined 
by ANOVA followed by Tukey-Kramer analysis. 
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migration (Fig.7A and Fig.7B). Propranolol also 
repressed AKT and S6 protein phosphorylation (Fig.8A 
and Fig.8B). An accumulation of LC3-II was also noted 
upon propranolol treatment but, on the contrary to lipin-1 
silencing, it induced an accumulation of p62 suggesting 
a blockage in the late phases of autophagy (Fig.8C and 
Fig.8D). This discrepancy with lipin-1 silencing alone is 
most likely due to the fact that propranolol completely 
inhibits all lipins while specific lipin-1 depletion 
with siRNA causes induction of lipin-2. As a whole, 
pharmacological inhibition of lipins confirmed their role 
in the regulation of the cell phenotype.
lipin-1 depletion or inhibition sensitizes cancer 
cells to rapamycin treatment
Rapamycin is a widely used anti-cancer agent. 
However, when used alone, it has often limited effects 
mainly due to the loss of negative feedback loops in 
cancer cells leading to reactivation of AKT and ribosomal 
protein S6. As we observed that phosphorylation of AKT 
and ribosomal protein S6 were decreased following 
lipin-1 silencing, we hypothesized that lipin-1 silencing 
could potentiate the anti-proliferative effect of rapamycin 
on cancer cells. A preliminary experiment showed that 
Fig.8: Propranolol inhibited AKt and s6 phosphorylation and induced lc3II and p62 accumulation. 24 h after treatment 
with 100 µM propranolol, PC-3 cells were processed for Western blotting and analysed with specific antibodies to AKT, Phospho-AKT 
(ser473), ribosomal protein S6, phospho-ribosomal protein S6(ser235/236), LC3, p62/SQSTM1 and Erk1/2. The results of each graph are 
expressed as means ± s.d. of three independent experiments. ***: p< 0.001 as determined by ANOVA followed by Tukey-Kramer analysis. 
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rapamycin treatment of PC-3 cells in a range of 10 nM 
to 1 µM induced a similar repression of proliferation. In 
the following experiments, concentrations of 20 and 50 
nM of rapamycin were used and gave similar results. 
Only the data with the 50 nM concentration are shown. 
While rapamycin treatment of PC-3 (Fig.9A and Fig.9C) 
and Hs578T cells (Fig.9B) reduced their proliferation rate 
by about 60 %, the combination of rapamycin treatment 
with lipin-1 silencing almost completely suppressed their 
proliferative capacities. Pharmacological concentrations 
of propranolol, alone or in association with rapamycin, 
also repressed cell proliferation by 40 or almost 100 %, 
respectively (Fig.9D) which further demonstrated the 
synergistic effect of targeting these two pathways. The 
potentiation of the effect of rapamycin by propranolol was 
confirmed by direct cell counting (Supplemental Fig.9).
dIscussIon
Deregulation of lipid metabolism in various 
cancer types makes it an attractive target for anti-cancer 
therapies. A first strategy to limit fatty acid availability 
would consist in inhibiting lipid synthesis [10]. This 
approach was largely used in recent research and led to the 
identification of several key enzymes for which targeting 
affected cancer cell proliferation and survival. Based on 
these data, specific inhibitors have been developed and 
are currently being tested in clinic (reviewed by [4-7]). 
Fatty acids level can also be decreased by enhancing their 
degradation, increasing their storage or blocking their 
release from storage. In the lipid storage pathway, lipin-1 
is one of the least studied enzymes in cancerogenesis 
[10]. We identified lipin-1 as a Rac1 regulated gene, 
probably through mTORC1 activation [25] that, in turn, 
regulates positively SREBP1 [26], a transcription factor 
Fig.9: Potentiation of the anti-proliferative effect of rapamycin by depletion or pharmacological inhibition of lipin-1. 
(A-C) Immediately after transfection of prostate adenocarcinoma (PC-3) or breast adenocarcinoma cells (Hs578T) with a control siRNA 
(Scr) or with an siRNA targeting lipin-1 (siLipin1(1) or siLipin1(2)) cells were seeded in 24-well plates and collected at the indicated times. 
Where indicated, the cells were cultured with 50 nM of rapamycin (+rapa). In D, PC-3 cells were treated with 50 nM rapamycin (rapa) 
and/or 100 µM propranolol (propr). The DNA content of each well was measured as described in “Materials and Methods”. *** p< 0.001 
ANOVA followed by Tukey-Kramer analysis.
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involved in lipin-1 gene expression [27]. Via mTORC1, 
Rac1 could also regulate lipin-1 phosphorylation and, 
consequently, its activity and its localization [28]. The 
high expression of lipin-1 in various cancer cell lines as 
well as its over-expression noticed in about 50 % of high 
grade prostate cancer samples prompted us to characterize 
its role in cancer cell phenotype. Most of our study was 
performed with prostate cancer cells as this type of cancer 
is especially dependent on an enhanced lipid metabolism 
[29]. In addition, lipin-1 depletion strongly inhibited 
cancer cells proliferation while it had only limited effect 
on non-cancerous cells. This is a key point for the clinical 
relevance of the targeting of this protein. The inhibition 
of lipin-1 did not significantly affect whole lipid synthesis 
and FASN expression. Lipin-1 is expected to regulate 
FASN expression through the inhibition of SREBP1 
activity. However, in our model, this transcriptional 
function of lipin-1 is likely repressed as lipin-1 seems 
highly phosphorylated by a mTOR-dependent pathway 
(Supplemental Fig.10A), a modification reported to 
prevent its entry into the nucleus [30]. This is in line 
with our observations showing that lipin-1 is exclusively 
located in the cytoplasm and never in the nucleus of 
high-grade adenocarcinoma cells in tumor samples. In 
prostate cancer cells, lipin-1 silencing is correlated with 
PA accumulation and reduced proliferation, while many 
reports indicate that increased concentration of PA is often 
correlated with a proliferative phenotype (for review see 
[31]). However, these data are not contradictory when 
considering the mechanisms leading to the increased 
intracellular levels of PA. When high concentration results 
from the stimulation of its synthesis (via phospholipase D, 
lysophosphatidic acid acetyltransferase or diacylglycerol 
kinase), it induces an increased proliferation rate. In 
our model, accumulation is due to a decrease in its 
conversion into DAG, which affects both PA- and DAG-
dependent signaling pathways and further impairs the 
production of phospholipids (phosphatidylethanolamine, 
phosphatidylcholine, …) used as building blocks for 
cell membranes. This mechanism has been proposed to 
explain the induction of cell death in U937 cells by a semi-
specific inhibitor targeting lipin-1 [32]. It has been shown 
that lipin-1 is induced in culture conditions where PA is 
up-regulated such as serum withdrawal (Supplemental 
Fig.10B and [33]) or hypoxia [34, 35] but also in response 
to exogenous PA (Supplemental Fig.10C) likely to 
regulate lipid homeostasis. Thus, lipin-1 depletion is likely 
to trigger both an imbalance between lipid species and a 
decrease in nutrient availability that might explain the 
decreased phosphorylation of AKT and ribosomal protein 
S6 and the increase in autophagy required to fuel the cells 
with building blocks and energy. Importantly, the loss of 
lipin-1 was recently reported to inhibit the clearance of 
autophagy in muscle cells [13]. However, this process 
does not seem to operate in prostate cancer cells depleted 
in lipin-1. The enhanced level of LC3-II noticed upon 
lipin-1 silencing was not associated with an up-regulation 
of p62/SQSTM1. In addition, we did not observe any 
accumulation of autophagosomes at the expense of 
autolysosomes. This discrepancy is likely related to our 
experimental model in which lipin-1 depletion is partially 
compensated by lipin-2 over-expression. This hypothesis 
is further supported by the observation that propranolol, 
a pharmacological molecule that completely inhibits 
all lipins, also induced both LC3II and p62/SQSTM1 
accumulation in PC-3 cells.
The inhibition of cell migration following lipin-1 
silencing further enhanced the relevance of lipin-1 to 
tumorigenesis. Here, we have demonstrated that this effect 
is related to an increased activation of RhoA, a data in 
agreement with previous report from our research group 
and others demonstrating that an increased activation of 
RhoA is sufficient to repress PC-3 cell migration [20, 36]. 
This RhoA activation in lipin-1-depleted cells could be 
related to the increased concentration of PA which can 
activate the sphingosine kinase-1 to produce sphingosine-
1-phosphate [37], a lipid mediator able to enhance RhoA 
activity [38], and to inhibit migration of various tumor 
cells including PC-3 [36, 38]. 
It was recently reported that lipin-1 depletion results 
in a reciprocal increase in lipin-2 but not lipin-3 expression 
[21]. A similar regulation was also observed here in 
prostate cancer cells suggesting that this mechanism is 
widespread. We further showed that overexpression of 
lipin-1 represses lipin-2 expression and that this feedback 
dynamic compensation is dependent on the catalytic 
activity of lipin-1, a mechanism that has to be taken into 
account in any strategy aiming at targeting lipins.
The PI3K/AKT/mTOR pathway is over-activated in 
several cancers including prostate cancers [39] and much 
effort has been devoted to its inhibition. Inhibition of the 
mTOR complex 1 with rapamycin or its analogs exerts an 
anti-tumoral activity in tumor cell lines and therapeutic 
response has been reported for some cancers [40-42]. 
However, in numerous cancer types including prostate 
cancer, mTOR complex 1 inhibition by rapamycin had 
a limited therapeutic efficacy in part due to the loss of 
negative feedback loops leading to the activation of AKT 
by TORC2 [43]. To overcome this resistance, rapamycin 
has been successfully combined with other drugs such 
as aromatase inhibitors [44] or HDAC inhibitors [45-
48]. Thus, the identification of proteins whose silencing 
synergizes with mTOR inhibition to decrease tumor 
growth is of particular interest [49]. The inhibition of AKT 
and ribosomal protein S6 activation following lipin-1 
silencing was the rationale to associate lipin-1 siRNA and 
rapamycin treatment. Since our data demonstrated that 
lipin-1 silencing sensitizes prostate and breast cancer cells 
to rapamycin, we then verified whether pharmacological 
inhibition of lipins activity could be considered as a 
potential therapeutic option or not. Propranolol was 
initially used as a beta-adrenoceptor antagonist. It 
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displays anti-tumor activity in neuroblastoma [50] and 
can potentiate chemotherapy in breast cancer [51]. It was 
later on found to be a potent inhibitor of lipins activity. 
Used alone, it recapitulates most of the effects of lipin-1 
silencing on PC-3 cells phenotype. Most interestingly, 
it fully sensitizes PC-3 cells to rapamycin treatment, 
similarly to what was observed by using a siRNA targeting 
lipin-1. Thus, our data opens the way to new anti-cancer 
strategies, especially by providing the rationale to combine 
two well-known molecules in human therapy, propranolol 
and rapamycin, for the treatment of cancer.
MAterIAls And Methods
reagents and cells
Bisbenzimide H 33258 was from Calbiochem 
(Merck, Overijse, Belgium). 1,2-Dioctanoyl-sn-glycerol 
3-phosphate sodium salt (P3591), rapamycin (R8781) 
and (+)-propranolol (P0884) were from Sigma. Rabbit 
anti-lipin-1 (#sc-98450), rabbit anti-lipin-2 (#sc-134433), 
mouse anti-ribosomal protein S6 (#sc74459), mouse anti-
phospho ribosomal protein S6 (ser235/236) (#sc293144), 
rabbit anti-p62/SQSTM1 (#sc28359) and mouse anti-
RhoA (#sc-418) were from Santa-Cruz Biotechnology 
(Bioconnect, The Netherlands). Mouse anti-Rac1 (23A8) 
was from Upsate Biotechnology. Mouse anti-human 
LC3 (#0260-100) was from Nanotools (Merck, Overijse, 
Belgium). Rabbit anti-AKT (#9272) and rabbit anti-
phosphoAKT(ser473) (#9271) were from Cell Signalling 
(Bioke, The Netherlands). Rabbit anti-Erk1/2 (#M-
5670) and mouse anti-phosphoErk1/2 (#M8159) were 
from Sigma. The secondary horseradish peroxydase 
conjugated rabbit anti-mouse IgG (P0260) and swine 
anti-rabbit IgG (P0217) were from DAKO (Heverlee, 
Belgium). Human prostate adenocarcinoma cells PC-3 
were cultured in F-12 Kaighn’s medium (Invitrogen, 
Merelbeke, Belgium) supplemented with 7% Foetal 
Bovine Serum (FBS) (Lonza, Verviers, Belgium). Human 
prostate carcinoma cells (LnCaP) and human immortalized 
prostatic cells (PNT1A) were cultured in RPMI 1640 
(Lonza) supplemented with 7% FBS. Human breast 
adenocarcinoma cells (Hs578T and MCF7), fibrosarcoma 
cells (HT1080), melanoma cells A2058, skin fibroblasts 
(FIBRO) and endothelial cells (LT2; human umbilical vein 
endothelium cells (HUVEC) immortalized by transfection 
with Large T SV40 antigen (a kind gift of E. Dejana, 
Milan)) were cultured in DMEM (Lonza) supplemented 
with 7% FBS. PC-3, Hs578T and MCF7 cells were 
authenticated through DNA profiling of 8 different and 
highly polymorphic short-tandem repeat loci (DSMZ, 
Braunschweig, Germany) in November 2013.
sirnA transfection
21-nucleotides long siRNAs chemically 
synthesized, desalted, deprotected and PAGE purified 
were from Eurogentec (Liège, Belgium). The 
sequences of the siRNAs targeting RhoA (siRhoA), 
Rac1 (siRac1 and siRac1#2) and of the control siRNA 
(siScr) were described and validated previously [20, 
52]. The sequences of siRNA used for repressing 




and 5’-GUUCAUGUUGUCAUCUCUCTT-3’) and 
siLipin-2 (5’-GAUGGCAGCUAUCAGUGUUTT-3’ and 
5’-AACACUGAUAGCUGCCAUCTT-3’). Each pair 
of oligoribonucleotides was annealed at a concentration 
of 20 μM in 50 mM NaCl, 1mM EDTA, 10 mM Tris-
HCl pH 7.5. siRNA transfection was carried out as 
previously described [53]. Briefly, calcium phosphate-
mediated transfection was performed overnight (14-16 h) 
on subconfluent cells at a final concentration of 20 nM 
siRNA. Cells were washed twice with PBS and once with 
complete medium, this last step being defined as time 0 
post-transfection. Cells were lysed for Western blot or RT-
qPCR analysis 48 hours post-transfection.
Western blotting
Cells were lysed in SDS-PAGE lysis buffer 
and proteins were separated by polyacrylamide gel 
electrophoresis. Proteins were transferred to a PVDF 
Transfer Membrane (NEN Life Science Products). 
Membranes were then blocked for 1 hour with 3 % dry 
milk in PBS-0.05 % Tween 20 and incubated for 4 h 
with the diluted primary antibody. Membranes were then 
washed three times, incubated in the diluted secondary 
horseradish peroxydase-conjugated antibody for 1 h, 
and revealed by chemoluminescence using the ECL kit 
(Amersham Biosciences) and X-ray film exposure. The 
membranes were re-probed with anti-Erk1/2 antibodies to 
control protein loading.
Immunohistochemistry
This protocol was established based on 
manufacturer’s instructions. Human prostate carcinoma 
paraffin embedded sections (5 µm) were dewaxed and 
rehydrated using the following successive baths: 8 min in 
xylol, 4 min in xylol, 2 min in 100 % ethanol, 2 min in 
95 % ethanol, 2 min in 70 % ethanol and 2 min in H2O. 
Antigen retrieval was performed by heating samples in 
REALtm Retrieval Solution (Dako) at 120°C for 5 min. 
After cooling, endogenous peroxydases were inhibited 
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using 3 % H2O2 during 20 min at room temperature (RT). 
Background staining was reduced by incubating the slides 
in 10 % FBS/PBS for 30 min at RT. Sections were then 
subsequently incubated with the primary anti-lipin-1 
antibody (dilution 1/100) for 1 h at RT then with the biotin 
conjugated anti-rabbit antibody (dilution 1/400) during 45 
min and then with HRP conjugated streptavidin (dilution 
1/400) during 30 min at RT. Staining was revealed using 
AEC+ High Sensitivity Chromogen (Dako) and sections 
were counterstained with haematoxylin.
lipid synthesis, triglycerides and phosphatidic 
acid concentration measurements
Rates of lipid synthesis and fatty acid beta-oxidation 
were assessed in PC-3 cells 24 h after transfection with the 
indicated siRNA. The lipid assay was based on the method 
of Lin and collaborators [54] with some modifications. 
Briefly, 24 h after transfection, PC-3 cells were incubated 
with [3H]acetate (2 μCi/ml; Perkin Elmer; used as a 
metabolic precursor of lipids) during 24 h Lipids were 
extracted using the chloroform–methanol method, and 
lipid radioactivity was measured by liquid scintillation 
(Lipoluma; Lumac). Triglycerides and phosphatidic acid 
content were measured in cells 48 h after transfection 
with the indicated siRNA. Lipids were extracted using 
the chloroform-methanol method. Triglycerides were 
measured by using a a colorimetric assay (Sigma, TR0100) 
and the phosphatidic acid content by using a fluorometric 
assay kit (Cayman chemical, 700240) following the 
instructions of the manufacturer.
Proliferation assay
Cells were seeded in 24 wells costar plates 
immediately after transfection with siRNA and collected 
at different time points to determine the DNA content by 
a fluorimetric technique [55] as previously described [56]. 
Briefly, cell layers were rinsed three times with saline and 
homogenized in PBS by sonication (20 s/well). 100 µl 
of each sample were transferred into a 96 well plate and 
supplemented with 100 µl of bisbenzimide solution (200 
µg/ml bisbenzimide, 4 M NaCl, 20 mM NaH2PO4, pH; 
7.4). In each plate a standard curve of DNA (from 2 µg 
to .03 µg) was included. The plate was mixed 5 min and 
fluorescence was read in a microplate spectrofluorometer 
SpectraMax Gemini XS (Molecular Devices, Sunnyvale, 
CA, USA) with an excitation wavelength of 355 nm and 
an emission wavelength of 460 nm. 
For cell counting, cells were seeded in 12 wells 
costar plates immediately after transfection with siRNA. 
Cells were detached at different time points with 2.5 % 
trypsin-EDTA, pelleted and suspended in 300 µL of PBS. 
Flow cytometry was performed on a BD FACSVerse (405 
nm, 488 nm, 633 nm, walk-away system) equipped with 
a “Optional Volumetric Flow Sensor” able to measure the 
volume over the entire acquisition time. 
Migration assay
PC-3 cells were seeded (3x104 cells per well) into 
sterile Culture-Insert (#80209, ibidi). After 24 h the 
inserts were removed revealing a gap of 500 µm width 
in the cell monolayer. This was defined as the 0 h time 
of the assay. Phase-contrast micrographs of the gap were 
taken, at two random positions for each assay, at time 
0 h and after 16 h using Nikon TiS microscope with a 
Clara High Resolution CCD camera (Andor), halogen 
Fiber Illuminator Intensilight, CFI Plan Fluor DL 10X 
0.30 objective (Nikon) and controlled by NIS-Elements 
software (Nikon). The surface of the remaining gaps was 
measured using NIS-Elements software (Nikon) and the 
covered surface was calculated by subtracting the 16 h gap 
from the 0 h gap. Bar = 250 µm.
GtPase activity assay
The assay was carried out as previously described 
[53, 57]. Briefly, cells were chilled on ice and lysed in 
ice-cold buffer containing 1 % Triton X-100, 25 mM 
HEPES pH; 7.3, 150 mM NaCl, 4 % glycerol, 0.1 mM 
AEBSF, 4 µg/ml aprotinin. Lysates were centrifuged for 
6 min at 16000 g. Supernatants were immediately frozen 
in liquid nitrogen and stored at –80°C until used. An 
aliquot of each supernatant collected before freezing was 
denatured in SDS-PAGE lysis buffer to measure the total 
RhoGTPase content by Western blotting. For pull-down 
assays, supernatants were incubated for 30 min with 30 
µg of GST-PBD protein containing the Cdc42 and Rac 
binding region of PAK-1B or 30 µg of GST-RBD protein 
containing the RhoA binding region of Rhotekin both 
affinity linked to glutathione-Sepharose beads. The beads 
were washed 4 times in lysis buffer and boiled in 60 µl 
SDS-PAGE lysis buffer.
real time quantitative Pcr
Total RNA was isolated from siRNA-transfected 
cells using the High Pure RNA isolation kit (Roche 
Molecular Biochemical). 1 µg of total RNA was reversed 
transcribed using SuperScript III Reverse Transcriptase 
(Invitrogen). Real time qPCR was performed in a final 
volume of 20 µl containing 2 µl of cDNA (corresponding 
to 10 ng of total RNA for Lipin-1, Lipin-2, Lipin-3, FASN, 
ACLY and MAGL amplification and corresponding to 0.1 
ng of total RNA for GAPDH amplification), 300 nM of 
each primer and 10 µl of the qPCR MasterMix Plus for 
SYBR® green (Eurogentec) in the StepOneTM Real-Time 
PCR system (Applied Biosystems, Halle, Belgium). The 
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results were analyzed with the StepOneTM Software and 
normalized to the GAPDH transcript.
Generation of Pc-3 clones overexpressing 
lipin-1 or lipin-1d678e under the dependence 
of doxycycline 
The entire coding sequence of human Lipin-1 
was amplified by RT-PCR (forward oligonucleotide 
5’-cacacagaattcgcgccgctcggtgcagacca-3’, 
reverse oligonucleotide 
5’-cacacactcgagtggcaagaggctgcttgggaca-3’) and cloned 
into the EcoRI/XhoI sites of pcDNA4/TO (Invitrogen) 
(pcDNA4/TO/Lipin1) and sequenced. The mutant 
Lipin1D678E was generated using a two-step PCR and 
two anti-complementary oligonucleotides possessing a 
point mutation (underlined in the sequences) as compared 
to the wild type sequence. Two overlapping fragments 
covering the entire coding sequence were first amplified 
from the pcDNA4/TO/Lipin1 using the following pairs of 
primers: 5’-cacacagaattcgcgccgctcggtgcagacca-3’ and 5’- 
gtcccatcaatctcagaaatgatgactttatcatccca-3’ (for the 5’PCR 
product) and 5’-cacacactcgagtggcaagaggctgcttgggaca-3’ 
and 5’- CATCATTTCTGAGATTGATGGGACAATTAC 
CAGATCA -3’ (for the3’PCR product). These two 
fragments were then mixed in equal amount, denatured, 
annealed and elongated before PCR amplification 
(using 5’-cacacagaattcgcgccgctcggtgcagacca-3’ and 
5’-cacacactcgagtggcaagaggctgcttgggaca-3’ as forward and 
reverse primers). The final full size and mutated product 
was then digested, cloned into the pcDNA4/TO (pcDNA4/
TO/Lipin1D678E) and sequenced to verify the presence 
of the mutation. Clones of PC-3 cells expressing a high 
level of tetracycline repressor (PC-3/TR) were previously 
described [52]. They were transfected with pcDNA4/
TO/Lipin1 or pcDNA4/TO/Lipin1D678E and selected 
in medium supplemented with 1 µg/ml blasticidin + 200 
µg/ml zeocinTM. Several clones overexpressing lipin-1 or 
lipin-1D678E in a doxycycline-dependent way (PC-3/TR/
Lipin1, PC-3/TR/Lipin1D678E) were isolated and used in 
this study.
Autophagy analyses
Autophagy flux was analyzed with the pBABE-
puro mCherry-EGFP-LC3B reporter plasmid purchased 
from Qiagen and previously described [58]. PC-3 cells 
were seeded in a 6 well plate. 24 hours after seeding cells 
were transfected with 1µg of plasmid for 20-24 h with 3 
µL GeneJuiceTM (Novagen) following the manufacturer’s 
protocol. The cells were washed and directly transfected 
with the indicated siRNA as described above. After 16 h 
the cells were washed again and seeded at subconfluence 
in µ-Slides 8-well (Ibidi). Images were acquired by 
fluorescence microscopy and the analyses were performed 
using ImageJ software. Micrographs of the cells were 
acquired in several focal planes and the analysis performed 
on the stacked images. Puncta structures mCherry-positive 
and expressing or not EGFP were quantified in more than 
50 cells per condition. The proportion of autophagosomes 
was expressed as the percent of puncta with both colors.
cell survival and apoptosis
Cell survival and apoptosis were evaluated by 
fluorescence-activated cell sorting after annexin V–
FITC and Propidium Iodide staining. Adherent cells 
were detached with 2.5 % trypsin-EDTA, pelleted and 
suspended in Annexin binding buffer (Annexin V-FITC 
Apoptosis Detection kit, Sigma) and incubated for 15 
min with Annexin V-FITC (270 ng/ml) and Propidium 
Iodide (1.1 µg/ml). Flow cytometry was performed on a 
FACSCanto II double LASER flow cytometer (UV, 488 
nm, 633 nm) (BD Biosciences) and data were analyzed 
using FACSDiva Software (BD Biosciences).
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